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Abstract
Up to 20% of patients with pilocytic astrocytoma (PA) experience
a poor outcome. BRAF alterations and Fibroblast growth factor re-
ceptor 1 (FGFR1) point mutations are key molecular alterations in
Pas, but their clinical implications are not established. We aimed to
determine the frequency and prognostic role of these alterations in a
cohort of 69 patients with PAs. We assessed KIAA1549:BRAF fusion
by ﬂuorescence in situ hybridization and BRAF (exon 15) mutations
by capillary sequencing. In addition, FGFR1 expression was ana-
lyzed using immunohistochemistry, and this was compared with
gene ampliﬁcation and hotspot mutations (exons 12 and 14) assessed
by ﬂuorescence in situ hybridization and capillary sequencing.
KIAA1549:BRAF fusion was identiﬁed in almost 60% of cases. Two
tumors harbored mutated BRAF. Despite high FGFR1 expression
overall, no cases had FGFR1 ampliﬁcations. Three cases harbored a
FGFR1 p.K656E point mutation. No correlation was observed be-
tween BRAF and FGFR1 alterations. The cases were predominantly
pediatric (87%), and no statistical differences were observed in mo-
lecular alterationsYrelated patient ages. In summary, we conﬁrmed
the high frequency of KIAA1549:BRAF fusion in PAs and its asso-
ciation with a better outcome. Oncogenic mutations of FGFR1, al-
though rare, occurred in a subset of patients with worse outcome. These
molecular alterations may constitute alternative targets for novel clini-
cal approaches, when radical surgical resection is unachievable.
Key Words: BRAF, Brain tumor, FGFR1, Glioma, Molecular diag-
nosis, Pilocytic astrocytoma, Prognosis.
INTRODUCTION
Pilocytic astrocytomas (PAs) are the major solid neo-
plasms in children and teenagers (1, 2). According to data
from the Central Brain Tumor Registry of the United States, it
is the main neoplasm in the 5- to 14-year-old range in the
United States (3). Similarly in Brazil, PAs are the second most
common neoplasm in pediatric patients after leukemias (4),
accounting for almost 20% of primary brain tumors in chil-
dren (5). Pilocytic astrocytomas are less frequent in adults in
whom they are associated with more aggressive clinical
courses (1, 6). According to the World Health Organization
(WHO), PAs are grade I tumors because of their well-limited
and usually indolent nature (1). The 5-year survival rate is
990% in children (1, 7), and 52% in adults (8). Despite the
overall good prognosis of PAs, up to 20% of patients will
have a poor outcome, with recurrence, growth of incompletely
resected lesions, or dissemination through the cerebrospinal
ﬂuid, and ultimately death due to disease (1, 7).
Pilocytic astrocytomas can occur throughout the neu-
raxis, but the most common location of sporadic tumors is the
cerebellum (1). Extracerebellar tumors, particularly those lo-
cated in the cerebral hemispheres and in the optic pathways,
have a known association with neuroﬁbromatosis 1 (NF1), a
familial tumor predisposition syndrome with autosomal domi-
nant inheritance (1, 9). Approximately 10% of all PAs are re-
lated to NF1 (NF1-PAs), and conversely, PAs are the most
frequent brain tumor related to NF1 (49% of cases) (10, 11).
When these PAs arise in locations where gross total resection is
difﬁcult to achieve, they usually follow a more benign course
than sporadic PAs (11).
Molecular studies based on the relationship between
PAs and NF1 allowed the discovery of germline and somatic
mutations with silencing of the tumor suppressor gene NF1 in
NF1-PAs. These were recently deﬁned as point mutations,
splice mutations or nonsense mutations (germline mutations)
and loss of heterozygosity and epigenetic changes, such as
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methylation of the gene (somatic mutations) (9). These mu-
tations result in loss of expression of neuroﬁbromin, which is
a negative signaling regulator of RAS proteins; this results in
an increase of activated RAS levels and further activation of
the mitogen-activated protein kinase (MAPK) pathway (12).
The constitutive activation of the MAPK pathway increases
survival and proliferation of cancer cells in various neo-
plasms (13, 14).
MAPK is a key signaling pathway in the development
of PAs; it is altered in up to 90% of cases (7, 15, 16). The
major alterations leading to constitutive activation of MAPK
in PAs are gene fusions and point mutations involving the
oncogene BRAF (7, 17Y23). Gene fusions between KIAA1549
and BRAF (KIAA1549:BRAF fusion) leading to the over-
expression of the fusion protein affects up to 80% of PAs.
There are decreasing rates with age, varying from 79% in
children younger than 10 years to 7% in patients older than
40 years (16, 20); this is associated with a better prognosis in
low-grade gliomas, including PAs (21). Less frequent fusions,
such as SRGAP3-RAF1 (24) and FAM131B-BRAF (25, 26),
have also been described. Another mechanism of sustained
BRAF activation in PAs is the point mutation V600E, which
results in an amino acid substitution at codon 600 in BRAF,
from a valine (V) to a glutamic acid (E) in the majority of
cases, leading to the activation of the kinase domain of this
oncogene (7, 18, 22, 27). Nevertheless, this ﬁnding is in-
frequent in PAs (approximately 6%) and may be detected
more frequently in other brain tumor types, such as glio-
blastomas (22, 28), gangliogliomas, and particularly, pleo-
morphic xanthoastrocytomas (960%) (16, 22).
Recent studies have identiﬁed upstream alterations in
the MAPK pathway, mainly in the tyrosine-kinase receptor
Fibroblast growth factor receptor 1 (FGFR1), leading to
constitutive activation of the growth cascade in PAs (15,
29). In contrast to the FGFR1 ampliﬁcation frequently ob-
served in breast, ovary, and lung cancer (30, 31), gene fu-
sions and duplications are described at low frequencies in
brain tumors such as glioblastomas (32) and pediatric dif-
fuse astrocytomas (16), respectively. In PAs, the newly
described alterations of FGFR1 are point mutations in the
hotspot tyrosine kinase region, affecting mainly the codons
546 (p.N546K Yasparagine-to-lysine substitution) and 656
(p.K656E Ylysine-to-glutamate substitution) of the gene in
extracerebellar PAs (15).
Despite the great improvement in the knowledge on the
molecular oncogenesis of PAs in the last years, the main
established prognostic factors for PAs remain in the clinical
features, such as patient’s age, feasibility of radical resection
of lesion (33Y35), exposure to radiation therapy (1), and the
sporadic or hereditary nature of the tumor (12). The prog-
nostic implications of BRAF and FGFR1 alterations have not
been fully explored, and advances in this ﬁeld might identify
potential targets for clinical treatment of PA, particularly for
the tumors located in eloquent areas where radical resection is
rarely achieved.
In this study, we aimed to determine the frequency of
the molecular alterations in BRAF and FGFR1 and to evaluate
the prognostic role of these oncogenes in a series of Brazilian
patients with PAs.
MATERIALS AND METHODS
Patients
Sixty-nine patients from the Barretos Cancer Hospital
(HCB) and the Hospital of Clinics of Faculty of Medicine of
Ribeirao Preto (HCRP), from 1993 to 2013, were included in this
study. The patients were clustered according to sex, age group
(e19 years old vs Q20 years old), clinical diagnosis of NF1
(conﬁrmed by standardized clinical criteria), and lesion location
(cerebellar vs extracerebellar). The outcome of patients was
classiﬁed as ‘‘favorable’’ (i.e. patients without any events and/
or with Karnofsky index Q80 at follow-up) and ‘‘unfavorable’’
(i.e. occurrence of some event and/or Karnofsky index e70 at
follow-up). We deﬁned ‘‘event’’ as death, growth of a partially
resected lesion, or the recurrence of a completely resected lesion
conﬁrmed by immediate postsurgical computed tomography
(36), detected either clinically and/or through neuroradiologic
examinations. The study was approved by both local Ethics
Committee (protocols HCB 87362 and HCRP 212.313).
The series included 38 male and 31 female patients
(ratio, 1.2:1), with ages ranging from 0.3 to 53.4 years old
(median, 9.1 years old). The 5-year and 10-year survival of
the series were 9 95% and 80%, respectively. Overall, 35
cases (50.7%) had unfavorable outcomes according to our
criteria: 8 patients (11.5%) had relapsing or growing residual
tumors; 23 patients (33.3%) developed moderate to severe
clinical deﬁcits (Karnofsky index, 50Y70); and 4 patients
(5.8%) died of disease. The deaths occurred after 1.7, 2.6, 6.5,
and 10.7 years of the diagnosis, respectively. Two deceased
patients had cerebellar lesions with subsequent medullary
dissemination of the tumor, 1 patient had a suprasellar lesion,
and the other had an insular tumor. Table 1 summarizes
clinical data of the patients.
Of the 69 patients included in this study, 5 had relapsed
lesions analyzed, and 1 of these had yet a second relapsed
lesion analyzed, totaling 75 samples. All cases were reviewed
by 2 neuropathologists, according to the 2007 WHO diag-
nostic criteria (1); negative immunohistochemical reaction to
mutated IDH1 was found in all cases (37, 38).
We constructed 2 blocks of tissue microarray (TMA)
from the formalin-ﬁxed, parafﬁn-embedded (FFPE) samples,
using the Beecher Instruments TMA platform, with tissue cores
at 1 mm diameter for the HCB cases and 1.5 mm for the HCRP
cases. Because of the histologic heterogeneity of the PAs, we
obtained up to 8 cores of each case (average, 3.6 cores/case),
representing the different histologic patterns of the tumors. In
9 cases, adjacent nonneoplastic cerebellar tissue was available
and included in the TMA.
Immunohistochemistry
Automated immunohistochemistry using Ventana Bench-
Mark Ultra equipment (Ventana-Roche, Tucson, AZ) was
performed in the TMA slides with 4-Km-thick tissue sections,
according to the manufacturer’s protocols. First, the sections
were deparafﬁnized and dehydrated, then the antigen retrieval
process was done with a mixed citrate/EDTA buffer (pH 6.0, at
125 -C for 4 minutes and 95 -C for 25 minutes in pressure
cooker). The monoclonal antibody used was anti-FGFR1 (Cell
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Signaling, Danvers, MA, clone D8E4, dilution 1:50). As ex-
ternal controls for the immunohistochemical reaction, we used
prostate epithelium and liver; internal control was the endothe-
lial cytoplasmic reaction.
The cytoplasmic expression of FGFR1 was evaluated in
a double-blind fashion following semiquantitative criteria
based on the intensity (0 = negative, 1 = weak, 2 = moderate,
3 = strong) and extension of the reaction (0, 0% of positive
cells; 1, G25% of positive cells; 2, 25%Y50% of positive cells;
and 3, 950% of positive cells) (39). With the sum of these
analyses, we achieved scores ranging from 0 to 6. Samples
with scores 0 to 2 were considered negative; those with scores
3 to 6 were considered positive (39). Tissues sections were
also evaluated for nuclear expression; Q25% nuclear staining
was considered positive, and cases with G25% of nuclear
staining were considered negative. In the cases with more than
1 tissue core, we calculated the average score.
KIAA1549-BRAF and FGFR1 Fluorescence In Situ
Hybridization Assay
For analysis of KIAA1549-BRAF fusion, ﬂuorescence in
situ hybridization (FISH) probes were created from BAC
clones containing human DNA from regions homologous to
the KIAA1549 and BRAF genes on chromosome 7, as identi-
ﬁed through the Ensembl Genome Browser (GRCh37). The
BRAF DNA was validated by polymerase chain reaction
(PCR) using the following sequences as primers: 5¶-CAGA
GTTTGTCAGATGGTCCCTTT-3¶ (forward) and 5¶-ACCATA
TAATAGAAGCGCCTCCCA-3¶ (reverse). For the KIAA1549
DNA, the validation sequences were 3¶-AGGTATTGTTGGA
ACATTGAAGGCT-3¶ (forward) and 5¶-CAGTCAAATGCTC
GCAATGAATGAA-3¶ (reverse). DNA inserts were extracted
from clone mini-cultures, puriﬁed and subjected to whole ge-
nome ampliﬁcation using the REPLI-g Midi Kit from Qiagen
(Cat# 150045, Qiagen, Du¨sseldorf, Germany).
An aliquot of 1 Kg of each puriﬁed BRAF and KIAA1549
DNA were labeled, respectively, with SpectrumRed and Spec-
trumGreen conjugated dUTPs using the Vysis Nick Translation
Kit (Cat# 32Y801300, Abbott Molecular, Des Plaines, IL), as
previously reported (40). Labeled DNA was coprecipitated
with herring sperm DNA as carrier (1:50) and human Cot-1
DNA (1:10) for blocking of repetitive sequences then diluted
1:10 in t-DenHyb hybridization buffer (Insitus Biotechnologies,
Albuquerque, NM). The labeled FISH probe mix was validated
for chromosome mapping and quality of hybridization in in-
terphase and metaphase cells prior to this study.
The FFPE slides were deparafﬁnized and dehydrated
according to previously established protocols (41). The probe
was applied to the selected areas, and hybridization was allowed to
occur at 37 -C for 40 to 67 hours and, ﬁnally, the chromatin was
counterstained with DAPI/anti-fade (0.3 Kg/mL in Vectashield
mounting medium, Vector Laboratories, Burlingame, CA).
Analysis was performed on an epiﬂuorescence microscope
using single interference ﬁlter sets for green (ﬂuorescein isothio-
cyanate), red (Texas red), and blue (DAPI), as well as dual (red/
green) and triple (blue, red, and green) band pass ﬁlters. For each
interference ﬁlter, monochromatic images were acquired and
merged using CytoVision (Leica Microsystems Inc., Wetzlar,
Germany). A minimum of 50 tumor nuclei was evaluated.
The specimen was considered positive for the KIAA1549:
BRAF fusion when there were doublets of red and green signals
very close or partially overlapping observed, as opposed to
signals separated by 92 signal diameters, which characterize
alleles with native status.
FGFR1 Ampliﬁcation
The FGFR1/CEP8 enumeration assay measured 2 ge-
nomic targets using 2 commercial FISH probes provided as
Analyte Speciﬁc Reagents (ASR) by Abbott Molecular (Ref. 08
N21-020 and Ref. 06 J37-018, respectively): Vysis LSI FGFR1
SpectrumRed FISH probe, which contains the entire FGFR1
gene, labeled with SpectrumRed ﬂuorophore, and the CEP
8 (D8Z2) FISH probe, labeled with SpectrumGreen ﬂuorophore.
The FFPE slides were processed and evaluated as pre-
viously described for the KIAA1549-BRAF fusion. The deter-
mination of low and high level of FGFR1 gene ampliﬁcation
followed the criteria proposed by Schultheis et al (42) based on
the ratio FGFR1/CEP 8 Q 2.0, or the average number of
FGFR1 signals per nucleus Q6 copies.
BRAF and FGFR1 Point Mutation Analyses
We ﬁrst obtained serial 10-Km-unstained sections of
FFPE blocks. One adjacent hematoxylin and eosinYstained
section was used for identiﬁcation and selection of tumor area
by the pathologist. DNA was isolated from 1 or 2 unstained
section from each specimen, depending on the size of the
tissue fragment, as previously described (43). Brieﬂy, tissues
were deparafﬁnized and dehydrated. Selected areas of tumor
were macrodissected using a sterile needle (18G 12) (Becton
Dickinson, Curitiba, Brazil), and carefully collected into a
microtube. DNA was isolated using QIAamp DNA Micro Kit
(Qiagen, Hilden, Germany), following the manufacturer’s in-
structions, followed by evaluation of DNA quantity and quality
by Nanodrop 2000 (Thermo Scientiﬁc, Wilmington, DE). DNA
samples were then diluted to a ﬁnal concentration of 50 ng/KL
and stored at j20 -C for further molecular analysis.
The whole exons of BRAF (exon 15; codon 600) and
FGFR1 (exons 12 and 14; codons 546 and 656) were ana-
lyzed by PCR, followed by direct sequencing, with emphasis
in the hotspot loci, as previously described (15, 28). Brieﬂy,
the PCR reaction was performed in a ﬁnal volume of 15 KL,
under the following conditions: 1 PCR buffer (Invitrogen,
Carlsbad, CA); 2 mmol/L MgCl2 (Invitrogen); 10 mmol/L
dNTPs (Invitrogen); 0.3 mmol/L of both sense and antisense
primers (Sigma Aldrich, St. Louis, MO); 1 unit of Platinum
Taq DNA polymerase (Invitrogen); and 50 ng of DNA. The
BRAF primers used were TCATAATGCTTGCTCTGATAG
GA (sense) andGGCCAAAAATTTAATCAGTGGA (antisense)
(28), for FGFR1 exon 12 TCAAGTCCCAGGGAAAAGCAG
(sense) and AGGCCTTGGGACTGATACCC (antisense), and
for FGFR1 exon 14 GACAAGTCGGCTAGTTGCAT (sense)
and CCCACTCCTTGCTTCTCAGAT (antisense). The PCR
was performed in Veriti 96-Wll Thermal Cycler (Applied
Biosystems, Austin, TX ). The PCR products were evaluated by
agarose gel electrophoresis prior to capillary sequencing.
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TABLE 1. Clinicoepidemiologic Data of the PA Series
ID Origin Sex Age (years) Location NF1 Extension of Ressection Event Status Folllow-Up (months)
1 P01 HCB M 4.8 C Total Recurrence AWD 27
2 P02 HCB M 4.2 C Total No AND 27.5
3 P03 HCB M 8.4 C Total No AND 36.2
**4 P04 HCB M 8 C Partial Growth AWD 34.1
*5 P05 HCB F 15.8 C Partial Growth AND 24.4
6 P06 HCB M 20.8 C Partial No AWD 16.8
7 P07 HCB F 35.4 SC Partial No AWD 22.9
8 P08 HCB M 4.8 C Partial Growth AWD 29.3
9 P10 HCB M 10.5 C Total No AND 43
10 P12 HCB M 5.2 C Total No AND 36.5
11 P13 HCB M 5.1 CH Partial No AWD 53.5
12 P16 HCB M 53.4 C Partial Growth AWD 34.1
13 P17 HCB F 19.2 C Total No AND 60.3
14 P18 HCB F 17 CH Total No AND 65.3
15 P20 HCB M 9.2 BS Partial No AWD 63.3
16 P21 HCB M 3.5 C Total No AND 66.6
17 P23 HCB M 16.4 CH Yes Total No AND 58.2
18 P24 HCB M 21.9 CH Partial No AWD 12.9
19 P25 HCB F 2.1 C Partial No AWD 7.1
20 P26 HCB M 10.2 C Total No AND 39.2
21 P28 HCB F 7.5 C Total No AND 86.3
22 P29 HCB F 5.2 C Total No AND 8.8
23 P30 HCB M 15.3 C Partial Growth AWD 8
24 P31 HCRP F 11.3 C Total No AND 133.2
25 P32 HCRP F 18.1 C Total Recurrence D 20.6
26 P33 HCRP F 13.8 C Partial No AWD 196.8
27 P34 HCRP M 5.2 SC Partial Growth AWD 194.7
28 P35 HCRP M 12.7 C Total No AND 179.1
29 P36 HCRP F 3.8 C Total Recurrence AND 168.6
30 P37 HCRP M 11.1 SS Partial No AWD 170.6
31 P38 HCRP F 9 SC Partial Growth AWD 155
32 P39 HCRP M 12.8 CH Partial Growth AWD 144.5
33 P40 HCRP F 3.6 C Total No AND 66.1
*34 P41 HCRP M 9.6 C Partial Growth D 128.8
35 P42 HCRP M 5.9 C Total No AND 51.7
36 P43 HCRP M 3.6 C Total No AND 116.5
37 P44 HCRP F 2 C Total No AND 115.7
38 P45 HCRP M 7.1 C Total No AND 112.8
39 P46 HCRP F 9.9 BS Partial No AWD 91.6
40 P47 HCRP M 17.4 CH Total No AND 63.7
41 P48 HCRP F 2.2 C Total No AND 83.2
42 P49 HCRP F 5.8 BS Partial No AWD 83.4
*43 P50 HCRP F 5.3 C Partial Growth AND 75.1
44 P51 HCRP M 27.7 C Total No AND 59.1
45 P52 HCRP F 16.2 SS Partial Growth D 79.2
46 P53 HCRP F 11.7 C Partial No AWD 68.6
47 P54 HCRP M 4.5 OP Partial Growth AWD 19.1
48 P55 HCRP F 0.3 CH Partial Growth D 31.5
49 P56 HCRP F 4.1 SS Partial No AWD 66.3
50 P57 HCRP F 5.7 C Total Recurrence AWD 58.3
51 P58 HCRP M 3.1 SS Partial Growth AWD 54.1
52 P59 HCRP M 14.7 CH Yes Total No AWD 58.7
53 P60 HCRP M 21.9 OP Partial No AWD 18.9
54 P61 HCRP M 32.2 CH Total No AND 10.2
55 P62 HCRP F 14.4 C Total No AND 45.1
(Continued on next page)
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The PCR products of each analyzed exon were ﬁrstly
puriﬁed with EXOSAP-IT (GE Technology, Cleveland, OH),
then, PCR products were submitted to a sequencing reaction
using 1 KL of BigDye (Applied Biosystems), 1.5 KL of se-
quencing buffer (Applied Biosystems) and 3.2 Kmol/L of
primer. The sequencing reaction was followed by post-
sequencing puriﬁcation with EDTA, alcohol and sodium cit-
rate. The puriﬁed products were eluted in HiDi (formamide)
and incubated at 90 -C for 5 minutes and at 4 -C for at least
5 minutes. Direct sequencing was carried out on a Genetic
Analyzer ABI PRISM\ 3500 (Applied Biosystems). The
analysis of each sample was done by comparison of eletro-
pherogram with Ensembl GeneBank sequence (BRAF:
ENSG00000157764 and FGFR1: ENSG00000077782).
All cases with mutations were conﬁrmed twice with a
new PCR and direct sequencing starting from extracted DNA.
In addition, for quality controls, a new DNA isolation and
further mutation analyses were performed in 10% of cases.
Statistical Analysis
Statistical analyses were performed with SPSS version
20 for Windowsi (IBM, Chicago, IL) with statistically sig-
niﬁcant values of p G 0.05. Differences in molecular alter-
ations of BRAF and FGFR1 between groups were veriﬁed by
the Fisher exact and the Pearson chi-square tests. Overall
survival (OS) and event-free survival (EFS) curves were de-
termined by the Kaplan-Meier method.
RESULTS
Molecular Characterization of BRAF
The FISH assay forKIAA1549:BRAF fusion detection was
successful in 64 (92.8%) of 69 primary lesions and in 4 of 5
relapsing lesions, which maintained the expression pattern of
their primary counterparts (Fig. 1A, B). Thirty-seven primary
lesions (57.8 %) displayed KIAA1549:BRAF fusion, with strong
positive association with a cerebellar location (p G 0.001), and
negative association with clinical diagnosis of NF1 (p = 0.011)
(Table 2). There was a tendency for this alteration to be detected
in the younger group, with 55.0% and 44.4% of patients posi-
tive for KIAA1549:BRAF fusion in the pediatric and adult
group, respectively (Table 2). Nevertheless, this difference was
not statistically signiﬁcant. In addition, there were no differ-
ences between groups for sex or outcome (Table 2).
Because of compromised DNA quality in some speci-
mens, we were able to obtain conclusive results of BRAF
point mutations in 48 (69.6%) of 69 primary lesions and in 5
of 5 recurrences. Two cases (4.2%) showed BRAF point mu-
tations (Fig. 1C, D). One recurrent suprasellar (hypothalamic)
tumor of an 11-year-old male patient (P37, Table 1) had the
p.V600E mutation, but the patient had only 1 sample avail-
able for molecular analysis, and this tumor was also positive
for the KIAA1549:BRAF fusion in the FISH assay. In addition,
a point mutation p.V600K, with a valine-to-lysine substitution
at the codon 600 (Fig. 1D), was detected in a cerebellar PA of
an 11-year-old female patient (P31, Table 1), who remains
alive without evidence of disease after a long follow-up (11
years). None of these patients with tumors harboring mutated
BRAF had the clinical diagnosis of NF1. Despite the small
number of BRAF-mutated cases, we performed statistical
analysis but did not identify signiﬁcant associations between
BRAF status and patients clinical features (Table 2).
Molecular Characterization of FGFR1
The immunohistochemical expression of FGFR1 was
tested in 74 of 75 samples. Nonneoplastic cerebellum showed
cytoplasmic staining only in Purkinje cells and was absent or
faintly expressed in the nonneoplastic astrocytes (Fig. 2A, B).
In tumor areas, cytoplasmic staining was detected in 51
(73.9%) of 69 primary tumors, regardless of the histologic
pattern of the PA (Fig. 2C, D) and no nuclear staining was
observed. Forty-nine cases (71%) had scores Q3, and 19 cases
(27.5%) were completely negative. No association was found
between FGFR1 immunohistochemical staining with the pres-
ence of the KIAA1549:BRAF fusion (p = 0.272), or with BRAF
point mutations (p = 0.456) (data not shown). No signiﬁcant
56 P63 HCRP F 16.7 CH Partial No AWD 47
57 P64 HCRP M 24.8 CH Partial No AWD 50.9
58 P65 HCRP F 9.1 SC Total No AND 46.1
59 P66 HCRP F 15.3 CH Yes Total No AWD 46.9
60 P67 HCRP M 7.2 BS Partial No AWD 49
61 P68 HCRP M 28.2 SC Partial No AWD 44.8
62 P69 HCRP M 4.1 SS Partial No AWD 34.7
63 P70 HCRP F 4.9 SS Partial Growth AWD 31
64 P71 HCRP M 5.7 C Partial Growth AWD 22.8
65 P72 HCRP M 17.4 CH Total Recurrence AWD 18.4
66 P73 HCRP F 6.9 OP Yes Partial No AWD 15.5
67 P75 HCRP F 11 CH Yes Partial No AWD 7.5
68 P76 HCRP F 8.5 OP Partial No AWD 7.6
*69 P77 HCRP M 12.5 C Partial Growth AWD 8.4
AND, Alive, no evidence of disease; AWD, alive, with disease; BS, brainstem; C, cerebellum; CH, cerebral hemispheres; D, death; F, female; M, male; SC, spinal cord; SS,
suprasellar; OP, optic pathway. *Patients with 2 samples in the TMA. **Patients with 3 samples in the TMA.
TABLE 1. (Continued)
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FIGURE 1. Molecular alterations in BRAF. (A, B) FISH assay for detection of KIAA1549:BRAF fusion showing a positive (A) and a
negative (B) case (white arrows). (C, D) Point mutations detected by Sanger sequencing for V600E (C) and V600K (D).
TABLE 2. Clinical Features of Patients and Their Association with BRAF Changes
KIAA1549:BRAF Fusion BRAF Point Mutation
(Total No. in the Series) Positive Negative p Wild Type Mutated p
Sex Female (31) 18 11 0.530 25 1 1.0
Male (38) 19 16 21 1
Age e19 years (60) 33 22 0.381 40 2 1.0
Q20 years (09) 4 5 6 0
NF1 Yes (05) 0 5 0.011 5 0 1.0
No (64) 37 22 41 2
Tumor location Cerebellar (36) 27 6 G0.0001 27 1 1.0
Extracerebellar (33) 10 21 19 1
Outcome Favorable (34) 22 16 0.987 26 1 1.0
Unfavorable (35) 15 11 20 1
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associations were seen between expression and clinical features
of the patients (Table 3).
Sanger sequencing for FGFR1 was performed in 45
(65.2%) of 69 primary lesions and in 5 of 5 relapsed lesions.
Among primary lesions, 3 (6.7%) of 45 carried the p.K656E
point mutation (Fig. 3A): an 18-year-old female (P32), a 3-
year-old male (P21), and a 2-year-old female (P44) patient.
All of these patients had cerebellar lesions (Tables 1 and 3).
The older patient had recurrence of a completely resected le-
sion 8 months after the ﬁrst surgery with cerebrospinal ﬂuid
dissemination despite adjuvant chemotherapy, and she died
21 months after the original surgery. On the other hand, the
youngest patient had the best outcome of the subgroup (i.e. no
evidence of disease after 9 years of follow-up), had a tumor
that was also positive for the KIAA1549:BRAF fusion by
FISH assay. No association was observed between FGFR1
mutation and the patients’ clinicopathologic characteristics
(Table 3) or FGFR protein expression (p = 0.086, data not
shown), as 2 of the 3 mutated cases had positive scores and 1
had a negative immunohistochemical score.
The FISH assay for FGFR1 was successful in 61 of the
69 primary lesions and in all 5 of the relapsed lesions; none
showed gene ampliﬁcation (Fig. 3B), but 7 (10.6 %) of 66 cases
had a low level of copy number gain (Fig. 3C), which was not
statistically related to any clinical feature (Table 3). The patient
who had a poor outcome (P32) had a concomitant FGFR1 point
mutation and low copy number gain of FGFR1 by FISH. The
association between low copy number gain of FGFR1 and the
immunohistochemical expression of FGFR1 was not signiﬁcant
(p = 0.091, data not shown).
Prognostic Role of BRAF and FGFR1
The Kaplan-Meier survival curves showed that the pres-
ence of KIAA1549:BRAF fusion was signiﬁcantly associated
FIGURE 2. Immunohistochemical expression of FGFR1. (A) In normal cerebellum, expression is limited to Purkinje cells. (B)
Neoplastic cells show overexpression when compared with nonneoplastic astrocytes (bottom). (C) Oligodendroglial pattern of PA,
showing moderate FGFR1 expression. (D) Piloid pattern of PA with similar FGFR1 expression.
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TABLE 3. Clinical Features of Patients and Their Association with FGFR1 Changes
FGFR1 Expression
p
FGFR1 lcng
p
FGFR1 Point Mutation
pPositive Negative Positive Negative Wild Type Mutated
Sex Female 22 9 0.994 3 24 1.0 23 2 1.0
Male 27 11 4 30 19 1
Age e19 years 43 17 0.758 6 47 0.922 37 3 1.0
Q20 years 6 3 1 7 5 0
NF1 Yes 4 1 1.0 0 5 1.0 5 0 1.0
No 45 19 7 49 37 3
Tumor location Cerebellar 27 9 0.446 5 26 0.425 24 3 0.264
Extracerebellar 22 11 2 28 18 0
Outcome Favorable 22 12 0.255 2 33 0.125 25 2 1.0
Unfavorable 27 8 5 21 17 1
Lcgn, low copy number gain.
FIGURE 3.Molecular alterations of FGFR1. (A) Electropherogram showing the point mutation K656E. (B, C) FISH assay displaying
a normal pattern (B), and a case with low-copy number gain of the FGFR1 signal (C). The amount of FGFR1 signals (green) did not
reach the cutoff value needed for the diagnosis of gene ampliﬁcation.
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with patients’ longer OS (p = 0.009) and EFS (p = 0.018)
(Fig. 4A. B). BRAF point mutations were not associated with
differences in the OS (p = 0.527), nor in the EFS (p = 0.317).
FGFR1 immunohistochemical expression and low copy
number gain were not correlated with OS (p = 0.103) or EFS
(p = 0.923). On the other hand, patients with the FGFR1
p.K656E point mutation had signiﬁcantly shorter OS (p =
0.047) and EFS (p = 0.025) when compared with patients with
wild-type tumors (Fig. 4C, D).
Finally, we assessed the combined impact of BRAF and
FGFR1 alterations in patients OS and EFS. We found that pa-
tients with tumors positive for KIAA1549:BRAF fusion showed
longer survival regardless of FGFR1 status and FGFR1 immu-
nohistochemical expression (Fig. 5A, B). Distinctively, among
the tumors negative for KIAA1549:BRAF fusion, the ones with
the FGFR1 pK656E point mutation had signiﬁcantly worse
prognosis (p = 0.002), whereas the overexpression of FGFR1
was related to a better prognosis (p = 0.03) (Fig. 5A, B).
DISCUSSION
We have shown in a series of 69 WHO grade I PAs that
KIAA1549:BRAF fusions are present in most of the cases and
that they are associated with better prognosis. In addition, we
found that FGFR1 is altered by oncogenic mutations in a
small subset (È7%) of cases that were associated with an
adverse outcome.
Despite the emergent interest in children’s brain tumors,
many studies have clustered PAs, diffuse astrocytomas (WHO
grade II), and other neoplasms in a set of ‘‘low-grade gliomas’’
(16, 21, 23, 44Y47). This has probably occurred because of the
rarity of these brain tumors compared with the much more fre-
quent adult tumors, such as glioblastoma (3). In addition, the
studies tend to isolate adults from children (6, 8). As far as we
are aware, this is the ﬁrst study with a cohort composed exclu-
sively of PAs, excluding the pilomyxoid astrocytoma variant of
PA (WHO grade II), and comparing different age groups.
FIGURE 4. (AYD) Kaplan-Meier curves showing the impact of KIAA1549:BRAF (K:B) fusion (A, B) and FGFR1 p.K656E point mu-
tation (C, D) in the overall survival and event-free survival of the patients.
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Herein, we were able to evaluate gene fusions and point
mutations in 67 of 69 cases and observed that nearly 60% of
them had alterations in BRAF and/or FGFR1, which are trig-
gers of the MAPK pathway, the dominant oncogenic pathway
of PAs (15, 19). The high incidence of KIAA1549:BRAF fu-
sion and its predominance in cerebellar lesions are in line with
previous studies (7, 15, 16, 24, 26), conﬁrming it as the most
frequent molecular change of PAs (7). In addition, 2 of 5 tumors
that harbored BRAF or FGFR1 mutations had a coexisting
KIAA1549:BRAF gene fusion. The occurrence of a concomi-
tant KIAA1549:BRAF fusion and other changes in the same
pathway is a rare occurrence, but it has been previously
reported (7, 21, 26). Finally, the negative relationship between
KIAA1549:BRAF fusions and clinical diagnosis of NF1 (thus
with alterations in the NF1 gene) has been previously reported
(7). Further studies on NF1 are necessary for a better under-
standing of this relationship.
The incidence of BRAF point mutations in our study
(4.2%) is also similar to published data (22). The presence of
this alteration did not show a clinical impact on prognosis,
thereby conﬁrming the previous ﬁndings of Bannykh et al,
who showed that the BRAF V600E mutation did not imply
higher aggressiveness to PAs (48). The usual p.V600E point
mutation was detected only in an 11-year-old male patient
who had an unstable hypothalamic lesion, which reinforces
the occurrence of this mutation in extracerebellar lesions (7).
Moreover, that patient also harbored the KIAA1549:BRAF
fusion. We also observed 1 unusual BRAF point mutation in
codon 600 of a cerebellar PA. The point mutation V600K was
found in an 11-year-old female patient who had an excellent
outcome after long follow-up (11.1 years). This mutation was
previously described in 5% to 15% of melanomas and was
related to metastatic disease and worse outcome (49Y51);
however, it has also been associated with a response to ﬁrst-
generation BRAF inhibitors (PLX4032, vemurafenib) (51).
Patients with PAs have experienced adverse results after
treatment with vemurafenib (52), as opposed to the good re-
sponse observed in patients with high-grade tumors (53, 54),
probably because of the overall low frequency of p.V600E.
Nevertheless, the subset of patients with KIAA1549:BRAF
positive tumors could potentially beneﬁt from treatment with
the second-generation BRAF inhibitors such as PLX-PB3,
which speciﬁcally target the fusion protein (52).
Most tumors in our series showed strong immunohis-
tochemical FGFR1 expression. These ﬁndings are in line with
a previous study in gliomas, in which FGFR1 overexpression
was detected, although the underlying molecular mechanism
was not explained at the time (55). Our FISH assays largely
eliminated ampliﬁcation as the underlying mechanism in the
PAs, contrary to what is seen in a subset of breast and lung
cancers (30, 31). FGFR1 low copy number gain was rare and
showed a nonstatistically signiﬁcant trend toward immuno-
histochemical overexpression (p = 0.094, data not shown).
The mutated form of FGFR1 was also not associated with
protein overexpression (p = 1.0).
With respect to the FGFR1 mutation, we observed
p.K656E point mutations at the tyrosine kinase domain in
6.7% of the PAs in this series, all of which were located in the
cerebellum. The oncogenic FGFR1 mutations, p.K656E and
p.N456K, were recently described by Jones et al (15) as re-
current events in extracerebellar PAs. Those mutations were
further described in rosette-forming glioneuronal tumor of the
fourth ventricle, but 1 of the patients in that series had an
earlier extracerebellar (diencephalic) PA with pilomyxoid
features, which also harbored the p.K656E mutation (29).
FGFR1 is currently an attractive therapeutic target, and
the immunohistochemical assessment of FGFR1 may repre-
sent a good indicator of the management of PAs. Recent
studies have related the efﬁcacy of novel speciﬁc FGFR1 in-
hibitors, such as ponatinib (AP 24534), in cases of lung cancer
with FGFR1 overexpression that were assessed by immuno-
blotting and mRNA quantiﬁcation (56). Besides this drug, other
FIGURE 5. Kaplan-Meier curves comparing the simultaneous impact of KIAA1549:BRAF (K:B) fusion and FGFR1 alterations on the
overall survival of patients. (A) Impact of FGFR1 p.K656E point mutation. (B) Impact of FGFR1 expression assessed by immuno-
histochemistry (positive score Q3; negative score e2).
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FGFR1 inhibitors, such as lucitanib (57) and CH5183284/
Debio 1347 (58), may constitute future alternatives for the
treatment of inoperable PAs. Nevertheless, further preclinical
and clinical studies are needed to determine whether FGFR1
expression and hotspot mutations will modulate and predict
patient response to these FGFR1-speciﬁc tyrosine inhibitors.
Concomitant KIAA1549:BRAF fusion and FGFR1 mu-
tations were not referred events in the study of Jones et al
(15), but this was detected in 1 of the patients of our series.
We further evaluated the impact of both the aforementioned al-
terations in the prognosis of the patients. The KIAA1549:BRAF
fusion had a positive impact on patients’ OS and EFS and was
conﬁrmed as a prognostic factor, corroborating the tendency to
better outcome of PAs, similar to what happens in the complex
group of low-grade gliomas described by Hawkins et al (21).
On the other hand, FGFR1 mutations were signiﬁcantly
related to PA patients’ shorter OS and EFS when compared
with the wild-type group; however, the signiﬁcance of this ﬁnd-
ing needs to be conﬁrmed in larger series. To our knowledge, this
the ﬁrst study to indicate the prognostic role of FGFR1 mutation
in PAs and their occurrence in cerebellar lesions.
In conclusion, we conﬁrmed the pivotal role of
KIAA1549:BRAF fusion and, to a lesser extent, of FGFR1 in
MAPK activation in PAs. More exactly, we showed the use-
fulness of evaluating the KIAA1549:BRAF fusion as a prog-
nostic biomarker, while FGFR1 mutation may be a relevant
prognostic marker in PAs. With further investigation, the
molecular changes of BRAF and FGFR1 may constitute po-
tential therapeutic targets for inoperable or recurrent PAs.
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